医渡科技（02158）今日盘中大涨5.57%，引起市场广泛关注。截至盘中11:36，该股报6.06港元，成交额达7497.34万港元。
消息面上，医渡科技公布其联属公司天津开心生活科技有限公司近期中标了一个重要项目。该项目是山东衍渡生物科技有限公司的重组人神经生长因子（SMR001）滴眼液Ⅲ期临床研究，总金额约为人民币5582万元。这一中标消息显然提振了投资者信心，推动股价上涨。
值得注意的是，医渡科技作为中国AI医疗变革的驱动者，其业务模式独具特色。公司基于自主研发的核心算法引擎YiduCore，构建了"数据—算法—场景"的飞轮闭环。这使得公司能够实现AI技术的高效率创新和低成本规模化应用，进而推动智能决策赋能"医—药—险—患者"全产业链生态。此次中标的临床研究项目，进一步彰显了医渡科技在医疗科技领域的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.